145 related articles for article (PubMed ID: 20399922)
1. Proof of concept for combined insertion of fluocinolone acetonide and glaucoma drainage implants for eyes with uveitis and glaucoma.
Ansari H; Kempen JH
Am J Ophthalmol; 2010 May; 149(5):699-700. PubMed ID: 20399922
[No Abstract] [Full Text] [Related]
2. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.
Malone PE; Herndon LW; Muir KW; Jaffe GJ
Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158
[TBL] [Abstract][Full Text] [Related]
3. Combined Ahmed Glaucoma Valve Placement, Intravitreal Fluocinolone Acetonide Implantation and Cataract Extraction for Chronic Uveitis.
Chang IT; Gupta D; Slabaugh MA; Vemulakonda GA; Chen PP
J Glaucoma; 2016 Oct; 25(10):842-846. PubMed ID: 27300641
[TBL] [Abstract][Full Text] [Related]
4. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis.
Bollinger K; Kim J; Lowder CY; Kaiser PK; Smith SD
Ophthalmology; 2011 Oct; 118(10):1927-31. PubMed ID: 21652079
[TBL] [Abstract][Full Text] [Related]
5. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.
Chieh JJ; Carlson AN; Jaffe GJ
Am J Ophthalmol; 2008 Oct; 146(4):589-594. PubMed ID: 18639220
[TBL] [Abstract][Full Text] [Related]
6. Long-term Outcomes of Glaucoma Drainage Implants in Uveitic Eyes With Fluocinolone Acetonide Implants.
Cao JL; Srivastava SK; Lowder CY; Sharma S; Baynes K; Eisengart J
J Glaucoma; 2020 Sep; 29(9):789-793. PubMed ID: 32404619
[TBL] [Abstract][Full Text] [Related]
7. Letter to the Editor: Long-term Outcomes of Glaucoma Drainage Implants in Uveitic Eyes With Fluocinolone Acetonide Implants.
Sharma S; Gupta R
J Glaucoma; 2021 Apr; 30(4):e190. PubMed ID: 33596022
[No Abstract] [Full Text] [Related]
8. Response to Letter to the Editor: Long-term Outcomes of Glaucoma Drainage Implants in Uveitic Eyes With Fluocinolone Acetonide Implants.
Cao JL; Eisengart J
J Glaucoma; 2021 Apr; 30(4):e190-e191. PubMed ID: 33769359
[No Abstract] [Full Text] [Related]
9. Uveitis treated with fluocinolone acetonide implants.
Viola F; Staurenghi G; Ratiglia R
Arch Ophthalmol; 2009 Jan; 127(1):115-6; author reply 116. PubMed ID: 19139357
[No Abstract] [Full Text] [Related]
10. Selective Laser Trabeculoplasty in Controlled Uveitis with Steroid-Induced Glaucoma.
Maleki A; Swan RT; Lasave AF; Ma L; Foster CS
Ophthalmology; 2016 Dec; 123(12):2630-2632. PubMed ID: 27594199
[No Abstract] [Full Text] [Related]
11. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial.
Friedman DS; Holbrook JT; Ansari H; Alexander J; Burke A; Reed SB; Katz J; Thorne JE; Lightman SL; Kempen JH;
Ophthalmology; 2013 Aug; 120(8):1571-9. PubMed ID: 23601801
[TBL] [Abstract][Full Text] [Related]
12. Pars plana vitrectomy, fluocinolone acetonide implantation, and silicone oil infusion for the treatment of chronic, refractory uveitic hypotony.
Dayani PN; Chow J; Stinnett SS; Jaffe GJ
Am J Ophthalmol; 2011 Nov; 152(5):849-56.e1. PubMed ID: 21794844
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Surgical Outcome After Ahmed Valve Implantation for Patients With and Without Fluocinolone Intravitreal Implant (Retisert).
Hennein L; Hou J; Stewart JM; Lowry EA; Jiang Z; Enanoria WT; Han Y
J Glaucoma; 2016 Sep; 25(9):e772-6. PubMed ID: 27552497
[TBL] [Abstract][Full Text] [Related]
14. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis.
Jaffe GJ; Ben-Nun J; Guo H; Dunn JP; Ashton P
Ophthalmology; 2000 Nov; 107(11):2024-33. PubMed ID: 11054326
[TBL] [Abstract][Full Text] [Related]
15. Iluvien Implantation for Uveitis and Uveitic Macular Edema.
Reddy AK; Burkholder BM; Khan IR; Thorne JE
Ocul Immunol Inflamm; 2018; 26(2):315-316. PubMed ID: 27736275
[No Abstract] [Full Text] [Related]
16. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant.
Parekh A; Srivastava S; Bena J; Albini T; Nguyen QD; Goldstein DA
JAMA Ophthalmol; 2015 May; 133(5):568-73. PubMed ID: 25719937
[TBL] [Abstract][Full Text] [Related]
17. Morphologic assessment for glaucoma in the Multicenter Uveitis Steroid Treatment (MUST) trial.
Gangaputra SS; Altaweel MM; Peng Q; Friedman DS; Rao PK; Foster CS; Kim RY; Reed SB; Srivastava SK; Wong IG; Kempen JH;
Ocul Immunol Inflamm; 2011 Aug; 19(4):267-74. PubMed ID: 21770805
[TBL] [Abstract][Full Text] [Related]
18. Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy.
Kempen JH; Van Natta ML; Friedman DS; Altaweel MM; Ansari H; Dunn JP; Elner SG; Holbrook JT; Lim LL; Sugar EA; Jabs DA;
Am J Ophthalmol; 2020 Nov; 219():303-316. PubMed ID: 32628922
[TBL] [Abstract][Full Text] [Related]
19. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
Arcinue CA; Cerón OM; Foster CS
J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752
[TBL] [Abstract][Full Text] [Related]
20. Fluocinolone acetonide intravitreal implant (Retisert
Leinonen S; Immonen I; Kotaniemi K
Acta Ophthalmol; 2018 Sep; 96(6):648-651. PubMed ID: 29655222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
